Lenvatinib, an oral TKI targeting VEGFR1–3, FGFR1–4, PDGFR-α, RET, and KIT, and inhibiting the pro-neoangiogenic and immunosuppressive effects of the tumour microenvironment, was tested in the open-label phase III REFLECT trial and shown to be non-inferior to sorafenib in terms of OS (13.6 vs. 12.3 months, hazard ratio 0.92).27 Here, RET is linked to neoplasm.